Bristol-Myers Squibb Company
ANTIBODY-DRUG CONJUGATE WITH A TUBULYSIN ANALOG WARHEAD HAVING A STABILIZED ACETATE GROUP IN THE TUV SUBUNIT

Last updated:

Abstract:

In antibody-drug conjugates having tubulysin analog as the warhead, according to formula (III) ##STR00001## the acetate group in the Tuv subunit (dotted box) demonstrates improved stability against hydrolytic cleavage.

Status:
Application
Type:

Utility

Filling date:

11 Jun 2019

Issue date:

26 Dec 2019